Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial.
about
Atherosclerosis and infection: is the jury still not in?Gut flora metabolism of phosphatidylcholine promotes cardiovascular diseaseImmunity, atherosclerosis and cardiovascular diseaseFungal rDNA signatures in coronary atherosclerotic plaques.New perspectives of infections in cardiovascular diseaseInfectious burden and risk of stroke: the northern Manhattan study.Infectious burden and carotid plaque thickness: the northern Manhattan study.Infection-mediated asthma: etiology, mechanisms and treatment options, with focus on Chlamydia pneumoniae and macrolides.Effect of clarithromycin treatment on Chlamydia pneumoniae in vascular tissue of patients with coronary artery disease: a randomized, double-blind, placebo-controlled trialMacrolide antibiotics and the risk of cardiac arrhythmiasInfectious burden: a new risk factor and treatment target for atherosclerosis.Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia.Cell wall-deficient bacteria as a cause of infections: a review of the clinical significance.Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trialThe gut microbiota, environment and diseases of modern society.Immune dysregulation mediated by the oral microbiome: potential link to chronic inflammation and atherosclerosis.Oral supplementation with non-absorbable antibiotics or curcumin attenuates western diet-induced atherosclerosis and glucose intolerance in LDLR-/- mice--role of intestinal permeability and macrophage activationImpact of seropositivity to Chlamydia pneumoniae and anti-hHSP60 on cardiovascular events in hemodialysis patientsCurrent understanding of the relationship between periodontal and systemic diseases.Cardiac risks associated with antibiotics: azithromycin and levofloxacinAcute coronary syndrome and chronic infection in the Cork coronary care case-control study.Design of the Trial to Assess Chelation Therapy (TACT)Periodontitis and coronary artery disease: a questioned association between periodontal and vascular plaques.Chlamydia pneumoniae--an infectious risk factor for atherosclerosis?Macrolide therapy for Chlamydia pneumoniae in the secondary prevention of coronary artery disease: a meta-analysis of randomized controlled trials.Influenza and cardiovascular disease: is there a causal relationship?Antibiotic trials for coronary heart disease.Chlamydia pneumoniae and atherosclerosis: no way-out or long way? What about renal failure patients?Beyond cholesterol--inflammatory cytokines, the key mediators in atherosclerosis.Infection with Chlamydia pneumoniae as a cause of coronary heart disease: the hypothesis is still untestedIntestinal microbiota determine severity of myocardial infarction in rats."Gum bug, leave my heart alone!"--epidemiologic and mechanistic evidence linking periodontal infections and atherosclerosis.Infection and Atherosclerosis DevelopmentUse of macrolides and tetracyclines for chronic inflammatory diseases.Oral health, atherosclerosis, and cardiovascular disease.Macrolides in cystic fibrosis.Managing Cardiovascular Risk of Macrolides: Systematic Review and Meta-Analysis.The effect of infections and vaccinations on stroke risk.Toll-like Receptors in the Vascular System: Sensing the Dangers Within.Development potential of rifalazil and other benzoxazinorifamycins.
P2860
Q22241306-81DD036B-6841-4385-9ED0-30EC67069772Q24601951-9EB649BC-1B87-4DD6-A530-632399D7647FQ28688590-A0145B67-84DD-447B-A6C7-9A19FF5330B9Q30835828-395282DB-9488-4D41-B32D-E4D6D98D56AEQ33587960-6ECCA54F-E7E0-4807-A417-394A7BA748F5Q33697873-691BDAF5-49D1-4553-9BF6-3F8BAC71F987Q33697959-12B9CE12-E22F-42D9-B4C5-3B0D619AAC75Q33706917-00AAFA69-319F-414A-A5C6-602D8B311D85Q33752851-4E4873D5-BDB1-4CDA-89C0-335CE2C649B0Q33772270-7E1DB54B-2322-40E5-9B01-9AB912A3FD78Q33936406-3E3AAC72-D648-4562-9A63-E58D25CDAB24Q33943151-E3189F39-D7D1-421E-82DE-3EC681E75C24Q33984369-F36D3AB7-6835-48FB-9E69-18C3BFD9C129Q34248742-E6317A9F-57B9-45B9-A8FA-49C2716DFBACQ34348985-926F2FC7-CFD6-4062-AE06-AB7B4AD70187Q34510105-97F0A250-075C-43E5-B478-FD52AD6AF983Q34664855-25EDB680-84A1-4D52-AE12-69C12562F50DQ34690945-2F25BA28-20B5-457B-BF4E-75B51A4E6080Q35222039-A0922ACD-B32B-4AE0-8CAB-DCED12B2AC4FQ35502601-1A7E96B0-5807-42DE-83BE-21B33ADD0062Q35583359-3D9C9909-9B2B-4046-A406-2024A2C155C9Q35627506-B8B0EFE8-546E-4DC6-8221-2750C644E6DBQ35660150-4727E8EE-0596-49F2-8BE8-9F64F1F4AD15Q35701591-FE9374F1-FEB3-4101-A2C6-A5298F115469Q35709736-DACD2790-8770-47BC-B828-89810C147695Q35733937-C3F0B4CA-56E8-4DB4-8B30-18DDE77EB146Q35733945-CE784538-3AF5-4344-989D-7A60C6140DFBQ35758705-DD048A66-46C5-4281-9FC3-905ACAF5CD9FQ35808632-1DD262B4-4458-4EC4-A779-CF8682F7DDE8Q35821202-2AF16F67-65DB-49E9-B581-00EDE6B3AEE7Q35863790-88B29767-7585-4BEE-A70A-0C1700EF7069Q35866675-EE63BB79-C421-4CA8-AB2E-CE8D9A7926FFQ35915081-3E92DFB7-03E7-4561-AB4C-50E40068B6B8Q35962028-52703677-6B25-4D29-9535-ED7F8DED45FCQ35969365-A7A93BAE-ACA4-4A00-96D1-959CACA27A41Q36309930-52AA10C1-84F1-4D95-A26B-9F8034706245Q36342810-1F9369E5-7692-4A44-9DBD-348EAAD887FBQ36390814-87E980A5-4FA9-4087-B1E5-065B942D115EQ36453194-2017D863-1F0A-45CF-868D-5576A0F2F49BQ36491823-E4EB4E4A-9210-4B69-8AAA-6622EF52EB8D
P2860
Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2003
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Azithromycin for the secondary ...... a randomized controlled trial.
@en
Azithromycin for the secondary ...... a randomized controlled trial.
@nl
type
label
Azithromycin for the secondary ...... a randomized controlled trial.
@en
Azithromycin for the secondary ...... a randomized controlled trial.
@nl
prefLabel
Azithromycin for the secondary ...... a randomized controlled trial.
@en
Azithromycin for the secondary ...... a randomized controlled trial.
@nl
P2093
P356
P1476
Azithromycin for the secondary ...... a randomized controlled trial.
@en
P2093
Investigators in the WIZARD Study
Joseph B Muhlestein
Marc A Pfeffer
Marian R Fisher
Michael W Dunne
Rebecca J Benner
Sandeep Gupta
Thomas D Cook
P304
P356
10.1001/JAMA.290.11.1459
P407
P577
2003-09-01T00:00:00Z